Kestra Medical Technologies (NASDAQ:KMTS) Research Coverage Started at Wolfe Research

Wolfe Research began coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS) in a report issued on Monday morning, MarketBeat.com reports. The firm issued an outperform rating and a $29.00 price objective on the stock.

Several other research analysts have also commented on the stock. Stifel Nicolaus began coverage on shares of Kestra Medical Technologies in a report on Monday. They issued a “buy” rating and a $28.00 price target for the company. Wells Fargo & Company initiated coverage on Kestra Medical Technologies in a report on Monday. They set an “overweight” rating and a $28.00 target price for the company. The Goldman Sachs Group initiated coverage on Kestra Medical Technologies in a report on Monday. They issued a “neutral” rating and a $24.00 price target on the stock. Finally, Piper Sandler assumed coverage on Kestra Medical Technologies in a research note on Monday. They set an “overweight” rating and a $27.00 price objective for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $27.67.

Kestra Medical Technologies Trading Up 4.6 %

Shares of KMTS opened at $25.70 on Monday. Kestra Medical Technologies has a 12-month low of $20.00 and a 12-month high of $26.06.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.